Package Leaflet: Information for theuser
Irbesartan Liconsa 150 mg tabletsEFG
Read all of this leaflet carefully before you start taking thismedicine because it contains important information for you.
Contents of thepackage leaflet:
Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that binds to receptors, causing blood vessels to constrict.
This results in an increase in blood pressure. Irbesartan prevents angiotensin-II from binding to these receptors, relaxing blood vessels and reducing blood pressure. Irbesartan slows the progression of kidney damage in patients with high blood pressure and type 2 diabetes.
Irbesartan is used in adults:
Do not take Irbesartan Liconsa
Warnings and precautions
Consult your doctor or pharmacist before starting to take irbesartan and if any of the following applies to you:
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Irbesartan Liconsa. Your doctor will decide whether to continue treatment. Do not stop taking Irbesartan Liconsa on your own.
See also the information under the heading “Do not take Irbesartan Liconsa.”
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor. It is not recommended to take irbesartan at the start of pregnancy (first 3 months) and it should not be taken if you have been pregnant for more than 3 months, as it may cause serious harm to your baby (see section Pregnancy).
Children and adolescents
This medicine should not be used in children and adolescents as the safety and efficacy have not been fully established.
Taking Irbesartan Liconsa with othermedicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Your doctor may need to modify your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Irbesartan Liconsa” and “Warnings and precautions”).
You may need to have blood tests if you are taking:
If you are using a type of pain reliever known as non-steroidal anti-inflammatory medicines, the effect of irbesartan may be reduced.
Taking Irbesartan Liconsa with food anddrinks
Irbesartan Liconsa can be taken with or without food.
Pregnancy andbreast-feeding
Pregnancy
You should inform your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant. Your doctor will normally advise you to stop taking irbesartan before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine to treat your high blood pressure.
It is not recommended to take irbesartan during the first few months of pregnancy and it should not be taken after the third month, as it may cause serious harm to your baby.
Breast-feeding
Inform your doctor if you are breast-feeding or about to start breast-feeding. It is not recommended to use irbesartan in women who are breast-feeding. Your doctor will advise you to use another treatment if you want to breast-feed, especially if your baby is a newborn or premature.
Driving and usingmachines
Irbesartan is unlikely to affect your ability to drive or use machines. However, during treatment for high blood pressure, dizziness or fatigue may occasionally occur.
If you experience these symptoms, consult your doctor before driving or using machines.
Irbesartan Liconsa contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Irbesartan Liconsa contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially “sodium-free”.
Follow exactly the instructions of administration of irbesartan indicated by your doctor. Consult your doctor or pharmacist if you have any doubts.
Method of administration
Irbesartan is administered orally. The tablets should be swallowed with a sufficient amount of liquid (e.g., a glass of water). Irbesartan can be taken with or without food. You should try to take your daily dose at the same time every day. It is important that you continue to take this medicine until your doctor tells you to stop.
The normal dose is 150 mg (1 tablet) once daily. Later, and depending on the response of the blood pressure, this dose may be increased to 300 mg once daily (2 tablets daily).
In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of kidney damage is 300 mg once daily (2 tablets daily).
Your doctor may advise a lower dose, especially at the start of treatment, in certain patients, such as hemodialysis patientsor patients over 75 yearsof age.
The maximum blood pressure-lowering effect should be achieved within 4-6 weeks after starting treatment.
Use in children and adolescents
Irbesartan should not be administered to children under 18 years of age. If a child swallows several tablets, contact your doctor immediately.
If you take more Irbesartan Liconsa than you should
If you accidentally take too many tablets, contact your doctor immediately.
If you forget to take Irbesartan Liconsa
If you accidentally miss a dose, simply take your normal dose when it is due. Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some of these side effects may be serious and may require medical attention.
As with similar medicines, in rare cases, the following allergic reactions have been reported in patients treated with irbesartan: skin reactions (rash, urticaria), as well as localized swelling in the face, lips, and/or tongue. If you think you may have such a reaction or experience difficulty breathing, stop taking irbesartan and seek immediate medical attention.
The following side effects have been reported:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
The side effects reported in clinical trials in patients treated with irbesartan were:
Since the marketing of irbesartan, the following side effects have been reported: dizziness, headache, altered taste, ringing in the ears, muscle cramps, muscle and joint pain, decreased red blood cell count (anemia - symptoms may include fatigue, headaches, difficulty breathing when exercising, dizziness, and pallor), reduced platelet count, abnormal liver function, high potassium levels in the blood, kidney function impairment, inflammation of small blood vessels, mainly in the skin area (a condition known as leucocytoclastic vasculitis), severe allergic reactions (anaphylactic shock), and low blood sugar levels. Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines and Healthcare Products Agency (AEMPS) website, www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.
The expiry date refers to the last day of the month stated.
Store in the original package to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Irbesartan Liconsa
Appearance of Irbesartan Liconsa and contents of thepack
Irbesartan Liconsa 150 mg tablets are white, cylindrical, and biconvex. The tablet can be divided into equal doses.
This medicine is available in blister packs of 14, 28, 56, or 98 tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder andmanufacturer
Marketing authorisation holder:
Laboratorios Liconsa, S.A.
C/Dulcinea S/N
Alcalá de Henares, 28805 Madrid, Spain
Manufacturer
Laboratorios Liconsa, S.A.
Avda. Miralcampo, Nº7, Polígono Industrial Miralcampo
19200 Azuqueca de Henares, Guadalajara, Spain
Date of last revision of this leaflet:January 2025
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/.